Researchers develop portable device for disease screening

Singapore researchers have developed a portable device that can accurately screen for several diseases and infections.

The enVision (enzyme-assisted nanocomplexes for visual identification of nucleic acids) platform was developed by researchers at the National University of Singapore (NUS). According to a press release, the device follows three key steps when screening for a disease: target recognition, target-independent signal enhancement and visual detection.  

NUS researcher Lim Geok Soon, PhD, said the device “employs a unique set of molecular switches, composed of enzyme-DNA nanostructures, to accurately detect, as well as convert and amplify molecular information into visible signals for disease diagnosis.”

“Each test is housed in a tiny plastic chip that is preloaded with a DNA molecular machine that is designed to recognize disease-specific molecules,” the release said. “The chip is then placed in a common signal cartridge that contains another DNA molecular machine responsible for producing visual signals when disease-specific molecules are detected.”

Researchers tested the device’s performance against the human papillomavirus, and it accurately detected different subtypes of the same disease and spotted differences within specific subtypes to identify other infections, the release stated.

The device takes 30 minutes to one hour to detect the presence of diseases and costs less than one Singapore dollar (73 cents). If it does detect a disease, the results can be further analyzed using a smartphone.

“The enVision platform is extremely sensitive, accurate, fast, and low-cost," research team leader Shao Huilin said in the release. "It works at room temperature and does not require heaters or special pumps, making it very portable. With this invention, tests can be done at the point-of-care, for instance in community clinics or hospital wards, so that disease monitoring or treatment can be administered in a timely manner to achieve better health outcomes."

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup